📇 Rhumatologue · NANCY · (54) · Libéral

M Rene LAVOT

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
146.3 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 NANCY (54)LibéralRPPS 10003806634

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR RENE LAVOT
54 RUE DU FAUBOURG DES 3 MAISONS, 54000 NANCY
☎ 0383364499Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia, Spain

The Pediatric infectious disease journal · 2025

📚 15 citations🎯 RCR 6.20🔓 Open Access

Lire l'abstract Crossref ↓

Background: In Catalonia, infants <6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyze nirsevimab’s effectiveness in hospital-related outcomes of the seasonal cohort (born during the RSV epidemic from October to January 2024) and compared them with the catch-up cohort (born from April to September 2023). Methods: Retrospective cohort study of all infants born between October 1, 2023, and January 21, 2024, according to their immunization with nirsevimab (immunized and nonimmunized). We followed individuals until the earliest of an outcome—hospital emergency visits, hospital admission or pediatric intensive care unit (PICU) admission due to RSV-associated or all-causes bronchiolitis—death or the end of the study. We used the Kaplan-Meier estimator and fitted Cox regression models using a calendar time scale to estimate hazard ratios (HRs) and their 95% confidence interval (CI). Sensitivity analysis was performed through matching. Results: Among 15,341 infants, a dose of nirsevimab led to an adjusted HR for hospital admission, PICU admission and emergency visits due to RSV bronchiolitis of 0.26 (95% CI: 0.17–0.39), 0.15 (95% CI: 0.07–0.28) and 0.46 (95% CI: 0.23–0.90), respectively. For all-causes bronchiolitis, the former adjusted HRs were 0.45 (95% CI: 0.31–0.63), 0.23 (95% CI: 0.13–0.41) and 0.49 (95% CI: 0.35–0.68), respectively. Conclusions: Nirsevimab was associated with reductions of 74% and 85% hospitalizations and PICU admissions regarding RSV-associated bronchiolitis, respectively. These percentages are slightly lower than those for the catch-up cohort. This information may help the implementation of RSV-immunization campaigns by public health authorities.

Chondroitin sulfate: From bioactive molecule to versatile drug delivery system for advancing regenerative medicine

International journal of biological macromolecules · 2025

📚 10 citations🎯 RCR 4.57

Kaixinsan regulates neuronal mitochondrial homeostasis to improve the cognitive function of Alzheimer's disease by activating CaMKKβ-AMPK-PGC-1α signaling axis

Phytomedicine : international journal of phytotherapy and phytopharmacology · 2024

📚 10 citations🎯 RCR 1.94

Cookies & analyse de trafic

M Rene LAVOT

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (24) — classées par pathologie

Transversal11

Épidémiologie & registres4

Revue générale4

Pédiatrie2

Revue / méta-analyse2

Santé mentale / fatigue2

Vraie vie / RWE2

SAPL1

Vascularites des gros vaisseaux1

Partager cette fiche